C4 Therapeutics (NASDAQ:CCCC) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.27) by 25.93 percent. This is a 45.95 percent increase over losses of $(0.37) per share from the same period last year. The company reported quarterly sales of $6.152 million which beat the analyst consensus estimate of $3.333 million by 84.56 percent. This is a 15.00 percent decrease over sales of $7.238 million the same period last year.